| |
Partnering
with Serometrix |
|
| |
Early
stage collaborations are critical to the efficient and timely development
of next generation therapeutics. The early integration of innovative
science with industry expertise reduces overall cost and risk, and
offers substantial long term returns by dramatically decreasing
the time from discovery to clinic. |
|
| |
|
|
| |
Current
Partnering Opportunities |
|
| |
SX-PCK9:
Compound Families inhibit PCSK9/LDLR to Lower Blood Cholesterol |
|
| |
Proprotein
convertase subtilisin-like/kexin type 9 (PCSK9) is a promising target
for prevention and treatment of cardiovascular disease, and a target
of commercial interest to many leading pharmaceutical companies.
Clearance of blood cholesterol depends upon the low density lipoprotein
receptor (LDLR) and PCSK9 binds to LDLR and increases its destruction.
Compounds that block PCSK9 binding to LDLR were discovered using
Serometrix’s Peptimer™ Discovery Platform. |
|
| |
Click
Here to receive a Non Confidential Summary of SX-PCK9 |
|
| |
SX-ARBC:
Compound Families target AR to Inhibit progression of Prostate Cancer |
|
| |
It
is certain that the Androgen Receptor (AR) drives prostate cancer
progression. AR regulates gene expression of more than 200 proteins
in the prostate. This family of compounds block attachment of the
AR to DNA gene promoters and are predicted to be more effective
than androgen removal for treatment of early and late stage prostate
cancer. Because of the low toxicity of these compounds and the potential
for specific targeting to prostate tissue, this family of compounds
offers potential for impeding benign prostatic hyperplasia (BPH)
progression to cancer. |
|
| |
Click
Here to receive a Non Confidential Summary of SX-ARBC |
|
| |
Collaborative
R&D Opportunities |
|
| |
SX-HIV1:
Integrase Strand Transfer Inhibitors |
|
| |
HIV
is demonstrating some resistance to most FDA-approved drugs on the
market. The persistence of the HIV virus lies in its biological
simplicity, nine genes coding 25 proteins, and its ability to survive
a high viral gene mutation rate.
The HIV integrase (IN) is a unique HIV protein, because it contains
mutation sensitive regions. Point mutation studies of HIV identified
specific amino acids that are critical to formation of an IN asymmetric
homo-multimer necessary for strand transfer integration of HIV genes
into human DNA, and to HIV survival.
Serometrix
is using its proprietary Peptimer™ discovery platform to discover
specific human-derived peptides that competitively block critical
HIV integrase multimerization steps in a targeted fashion. Serometrix
seeks an exclusive collaborative partner for further research and
development of the company’s HIV Integrase compounds, as well as
several additional compound discoveries that are anticipated during
this project. |
|
| |
Click
Here to receive a Non Confidential Summary of SX-HIV1 |
|
| |
Other
Collaborative Research Opportunities |
|
| |
Serometrix
is interested to explore opportunities for other research programs
of interest to our potential partners, which meet this general criteria: |
|
| |
-
a
validated regulatory protein pathway of commercial interest;
-
a partner who has developed or will develop relevant in
vitro and in vivo validation models; and
-
a collaborative arrangement that rewards success and allows
for strong interaction between Serometrix and its partner's
scientists.
|
|
| |
Partnering
Events |
|
| |
You
may want to meet with one of our team members at the following events: |
|
 |
|
|
